{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:18:56Z","timestamp":1762867136952},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T00:00:00Z","timestamp":1496707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.diagmicrobio.2017.05.012","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T11:15:14Z","timestamp":1496142914000},"page":"83-85","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines"],"prefix":"10.1016","volume":"89","author":[{"given":"Debora","family":"Sweeney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean L.","family":"Shinabarger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Bruss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris M.","family":"Pillar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0005","first-page":"1","article-title":"Characterization of the in vitro activity of novel lipoglycopeptide antibiotics","volume":"16","author":"Arhin","year":"2010","journal-title":"Curr Protoc Immunol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.diagmicrobio.2008.05.009","article-title":"Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters","volume":"62","author":"Arhin","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0020","series-title":"CLSI document M26-A","article-title":"Methods for determining bactericidal Activity of antimicrobial Agents; approved guideline","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"1999"},{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0025","series-title":"CLSI document M100-S24","article-title":"Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0030","series-title":"CLSI document M07-A10","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0035","series-title":"CLSI document M100-S26","article-title":"Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.diagmicrobio.2016.08.005","article-title":"Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014)","volume":"86","author":"Duncan","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0045","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0050","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1128\/AAC.01398-07","article-title":"In vitro activity of telavancin against resistant gram-positive bacteria","volume":"52","author":"Krause","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0055","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/00365548.2012.669843","article-title":"Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin","volume":"44","author":"Marconescu","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0060","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.04052-14","article-title":"Baseline activity of telavancin against gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2011.05.012","article-title":"Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010)","volume":"71","author":"Mendes","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0070","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1179\/joc.2010.22.5.304","article-title":"Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections","volume":"22","author":"Pfaller","year":"2010","journal-title":"J Chemother"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0080","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/JCM.02411-06","article-title":"Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent","volume":"45","author":"Rennie","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0085","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.diagmicrobio.2016.12.010","article-title":"Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus Aureus isolates from cancer patients","volume":"87","author":"Rolston","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2017.05.012_bb0090","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/JCM.01210-14","article-title":"Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method","volume":"52","author":"Ross","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0095","article-title":"Assessment of minimum inhibitory concentrations of telavancin by revised broth microdilution method in phase 3 hospital-acquired pneumonia\/ventilator-associated pneumonia clinical isolates","volume":"7","author":"Smart","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0100","series-title":"Proceedings of the 55th Interscience conference on antimicrobial Agents and chemotherapy (ICCAC), sept. 18th-21st, 2015, San Diego, USA","article-title":"Comparison of the in vitro bactericidal activity of eight agents against MRSA","author":"Sweeney","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2017.05.012_bb0105","series-title":"Vibativ, package insert","author":"Theravance Inc.","year":"2014"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317301724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317301724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T09:58:28Z","timestamp":1535795908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317301724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0732889317301724"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.05.012","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}